Aprea Granted European Orphan Drug Designation for APR-246 in Ovarian Cancer

News   Jan 24, 2015

 
Aprea Granted European Orphan Drug Designation for APR-246 in Ovarian Cancer
 
 
 

RELATED ARTICLES

Cryo-EM Reveals Interaction Between Major Drug Targets

News

For the first time, scientists have visualized the interaction between two critical components of the body's vast cellular communication network, a discovery that could lead to more effective medications with fewer side effects for conditions ranging from migraine to cancer.

READ MORE

New Ovarian Cancer Target

News

Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.

READ MORE

Sartorius Stedim Biotech and Siemens Sign Automation Agreement

News

Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE
 

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy